世界のウェアラブルインジェクター市場は、2021年の72億ドルから2026年までに115億ドルに達し、予測期間中のCAGRは9.9％と予想されます。この市場の成長を促す主な要因としては、COVID-19のため医療提供が在宅医療へ移行していること、さまざまな薬剤の投与におけるウェアラブルインジェクターの利点、慢性疾患（癌、糖尿病、CVDなど）の有病率の増加、主要市場における有利な保険適応シナリオ、インジェクターデバイスの技術的進歩、などが挙げられます。しかし、発展途上国における代替ドラッグデリバリー法の優先的使用、高額なコスト、医療制度の不備などが、ウェアラブルインジェクターの導入をある程度妨げることが予想されます。
COVID-19のパンデミックは、ウェアラブルインジェクター市場にプラスの影響を与えると予想されます。COVID-19に対応して、COVID-19患者の治療が最優先事項として、医療機関全体で医療の優先順位が変更されました。これが、ウェアラブルインジェクター市場の成長に影響を与えています。ウェアラブルインジェクターは、自動インジェクターと診療所でのケアの間のギャップを埋めるための重要なプラットフォームです。
ウェアラブルインジェクターは、医療インフラに接続された医療サービスの重要なギャップを埋めることが期待されています。COVID-19の罹患率に起因する慢性疾患の増加は、慢性の肺、心血管、および神経学的疾患の患者が疾患の長期的影響を管理し始めるため、ウェアラブルインジェクターの普及拡大を部分的に促進します。慢性疾患の患者は、診療所でのCOVID-19曝露から身を守るために、診療所から在宅ドラッグデリバリーへの移行を要求しています。
また、免疫不全疾患のような疾患はワクチン耐性をもたらすだけでなく、COVID-19による患者の長期にわたる病気の素因となるという理解が深まり、患者はより注意を払っています。注入療法は、特殊医薬品市場で350億ドルを占めています。これらの治療を病院や診療所から在宅医療に移行することで、患者と医療費支払者の両方に30〜70％のコスト削減がもたらされると推定されています。ウェアラブルインジェクターソリューションは、ポンプが数分、さらには数時間にわたって大量に投与するように設計されているため、点滴療法に特に適しています。化学療法、モノクローナル抗体、および自己免疫、血液、および遺伝性疾患を標的とする薬物を含む生物製剤および高粘度薬物は、一般に、自宅での患者ケアをサポートするために、また診療所でのケアの代替として、ウェアラブルインジェクターデバイスと組み合わせて使用されます。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 18)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 WEARABLE INJECTORS MARKET SEGMENTATION
FIGURE 2 WEARABLE INJECTORS MARKET, BY REGION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 1 STANDARD CURRENCY CONVERSION RATES
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 23)
2.1 RESEARCH DATA
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 4 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (WEARABLE INJECTORS MARKET)
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC.
FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: WEARABLE INJECTORS MARKET (2020)
FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE WEARABLE INJECTORS MARKET (2021-2026)
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 12 BOTTOM-UP APPROACH
FIGURE 13 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 14 DATA TRIANGULATION METHODOLOGY
2.4 MARKET RANKING ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
2.7 COVID-19 HEALTH ASSESSMENT
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE WEARABLE INJECTORS MARKET
FIGURE 15 WEARABLE INJECTORS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 16 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 17 WEARABLE INJECTORS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)
FIGURE 18 WEARABLE INJECTORS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 19 GEOGRAPHIC SNAPSHOT OF THE WEARABLE INJECTORS MARKET
3 EXECUTIVE SUMMARY (Page No. - 38)
4 PREMIUM INSIGHTS (Page No. - 43)
4.1 WEARABLE INJECTORS MARKET OVERVIEW
FIGURE 20 SHIFT OF HEALTHCARE DELIVERY TOWARD HOMECARE DUE TO COVID-19 IS DRIVING MARKET GROWTH
4.2 NORTH AMERICAN WEARABLE INJECTORS MARKET, BY COUNTRY AND THERAPY
FIGURE 21 DIABETES SEGMENT COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
4.3 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 22 MARKET IN CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
4.4 WEARABLE INJECTORS MARKET: REGIONAL MIX
FIGURE 23 NORTH AMERICA IS THE LARGEST MARKET FOR WEARABLE INJECTORS
5 MARKET OVERVIEW (Page No. - 47)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 24 WEARABLE INJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Shift of healthcare delivery toward homecare due to COVID-19
5.2.1.2 Advantages of wearable injectors in the administration of various drugs
5.2.1.3 Growing prevalence of chronic diseases
5.2.1.4 Favorable reimbursement scenario in major markets
5.2.1.5 Technological advancements and design development
5.2.2 RESTRAINTS
5.2.2.1 Preference for alternative drug delivery modes
5.2.2.2 High cost of wearable injectors
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for biologics and mAbs
FIGURE 25 US: BIOLOGIC MEDICINES IN DEVELOPMENT, 2017
5.2.4 CHALLENGES
5.2.4.1 Unfavorable reimbursement structure in developing countries
6 INDUSTRY INSIGHTS (Page No. - 52)
6.1 TECHNOLOGY ANALYSIS
6.2 PRICING ANALYSIS
TABLE 2 AVERAGE SELLING PRICE: WEARABLE INJECTORS
6.3 VALUE CHAIN ANALYSIS
FIGURE 26 WEARABLE INJECTORS MARKET: VALUE CHAIN ANALYSIS
6.4 ECOSYSTEM MARKET MAP
FIGURE 27 WEARABLE INJECTORS MARKET: ECOSYSTEM MARKET MAP
6.5 SUPPLY CHAIN ANALYSIS
FIGURE 28 WEARABLE INJECTORS MARKET: SUPPLY CHAIN ANALYSIS
6.6 PORTER’S FIVE FORCES ANALYSIS
FIGURE 29 PORTER’S FIVE FORCES ANALYSIS (2020): WEARABLE INJECTORS MARKET
TABLE 3 WEARABLE INJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS
6.6.1 THREAT OF NEW ENTRANTS
6.6.1.1 Growth in the overall wearable injectors market
6.6.1.2 Growing consolidation
6.6.1.3 Poor financing environment
6.6.2 THREAT OF SUBSTITUTES
6.6.3 BARGAINING POWER OF SUPPLIERS
6.6.4 BARGAINING POWER OF BUYERS
6.6.5 INTENSITY OF COMPETITIVE RIVALRY
6.7 REGULATORY ANALYSIS
6.8 PATENT ANALYSIS
6.8.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS
FIGURE 30 GLOBAL PATENT PUBLICATION TRENDS (2015-2020)
6.9 IMPACT OF COVID-19 ON THE WEARABLE INJECTORS MARKET
7 WEARABLE INJECTORS MARKET, BY TYPE (Page No. - 62)
7.1 INTRODUCTION
TABLE 4 WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
7.2 ON-BODY INJECTORS
7.2.1 ON-BODY INJECTORS SEGMENT DOMINATED THE MARKET IN 2020
TABLE 5 ON-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
7.3 OFF-BODY INJECTORS
7.3.1 OFF-BODY INJECTORS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 6 OFF-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
8 WEARABLE INJECTORS MARKET, BY TECHNOLOGY (Page No. - 66)
8.1 INTRODUCTION
TABLE 7 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
8.2 SPRING-BASED TECHNOLOGY
8.2.1 SPRING-BASED TECHNOLOGY ENABLES THE DELIVERY OF DRUGS WITH HIGHER VOLUME AND VISCOSITY
TABLE 8 WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
8.3 MOTOR-DRIVEN TECHNOLOGY
8.3.1 THESE DEVICES CAN GENERATE HIGH FORCE FOR SUBCUTANEOUS INJECTIONS OF HIGH-VISCOSITY LIQUIDS
TABLE 9 WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
8.4 ROTARY PUMP TECHNOLOGY
8.4.1 THESE DEVICES SHOW HIGH PRECISION AND THE POSSIBILITY TO NOT ALTER THE FLUID PROPERTIES
TABLE 10 WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
8.5 EXPANDING BATTERY TECHNOLOGY
8.5.1 EXPANDING BATTERY TECHNOLOGY SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 11 WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
8.6 OTHER TECHNOLOGIES
TABLE 12 WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2019-2026 (USD MILLION)
9 WEARABLE INJECTORS MARKET, BY THERAPY (Page No. - 73)
9.1 INTRODUCTION
TABLE 13 WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
9.2 DIABETES
9.2.1 HIGH PREVALENCE OF DIABETES ACROSS THE GLOBE TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
TABLE 14 INSULIN DEVICES AVAILABLE FOR DIABETES PATIENTS
TABLE 15 WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2019-2026 (USD MILLION)
9.3 IMMUNO-ONCOLOGY
9.3.1 IMMUNO-ONCOLOGY SEGMENT TO WITNESS NEGATIVE GROWTH DURING THE FORECAST PERIOD
TABLE 16 WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
9.4 CARDIOVASCULAR DISEASES
9.4.1 CARDIOVASCULAR DISEASES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 17 WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
9.5 OTHER THERAPIES
TABLE 18 WEARABLE INJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019-2026 (USD MILLION)
10 WEARABLE INJECTORS MARKET, BY END USER (Page No. - 80)
10.1 INTRODUCTION
TABLE 19 WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.2 HOSPITALS AND CLINICS
10.2.1 HOSPITALS AND CLINICS ARE THE LARGEST END USERS OF WEARABLE INJECTORS
TABLE 20 WEARABLE INJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2019-2026 (USD MILLION)
10.3 HOME HEALTHCARE SETTINGS
10.3.1 HOME HEALTHCARE SETTINGS SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD
TABLE 21 WEARABLE INJECTORS MARKET FOR HOME HEALTHCARE SETTINGS, BY COUNTRY, 2019-2026 (USD MILLION)
11 WEARABLE INJECTORS MARKET, BY REGION (Page No. - 84)
11.1 INTRODUCTION
FIGURE 31 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 22 WEARABLE INJECTORS MARKET, BY REGION, 2019-2026 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 32 NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT
TABLE 23 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY,2019-2026 (USD MILLION)
TABLE 24 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 25 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 26 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 27 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.2.1 US
11.2.1.1 Growing IV infusion expenditure is a key factor driving the US market.
TABLE 28 US: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 29 US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 30 US: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 31 US: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Rising prevalence of chronic diseases in Canada to drive the demand for drugs that can be self-administered
TABLE 32 CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 33 CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 34 CANADA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 35 CANADA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3 EUROPE
FIGURE 33 EUROPE: WEARABLE INJECTORS MARKET SNAPSHOT
TABLE 36 EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 37 EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 38 EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 39 EUROPE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 40 EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Availability of government support for drug development and approval to drive growth in the German wearable injectors market
TABLE 41 GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 42 GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 43 GERMANY: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 44 GERMANY: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.2 UK
11.3.2.1 Government focus on biosimilar innovation to drive the market growth
TABLE 45 UK: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 46 UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 47 UK: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 48 UK: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 100% coverage for diabetes by SHI to drive market growth in France
TABLE 49 FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 50 FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 51 FRANCE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 52 FRANCE: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.4 REST OF EUROPE
TABLE 53 ROE: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 54 ROE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 55 ROE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 56 ROE: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4 ASIA PACIFIC
TABLE 57 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 58 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 59 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 60 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 61 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Large number of patients suffering from diabetes, CVD, and other chronic conditions to drive market growth in Japan
TABLE 62 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 63 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 64 JAPAN: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 65 JAPAN: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Large diabetic population to drive market growth in China
TABLE 66 CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 67 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 68 CHINA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 69 CHINA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Large diabetic population to drive the market for wearable injectors in India
TABLE 70 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 71 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 72 INDIA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 73 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 74 ROAPAC: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 75 ROAPAC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 76 ROAPAC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 77 ROAPAC: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER CHRONIC CONDITIONS TO DRIVE THE MARKET IN LATIN AMERICA
TABLE 78 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 79 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 80 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 81 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 DEMAND FOR WEARABLE INJECTORS IN THE MANAGEMENT OF DIABETES AND CVD IS EXPECTED TO INCREASE IN THE MIDDLE EAST AND AFRICA
TABLE 82 CONFERENCES IN THE MIDDLE EAST AND AFRICA (2016-2018)
TABLE 83 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 84 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 85 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION)
TABLE 86 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 125)
12.1 INTRODUCTION
FIGURE 34 KEY MARKET DEVELOPMENTS (JANUARY 2018 TO JULY 2021)
12.2 REVENUE ANALYSIS OF KEY MARKET PLAYERS
FIGURE 35 REVENUE ANALYSIS OF THE KEY PLAYERS OPERATING IN THE WEARABLE INJECTORS MARKET
12.3 MARKET SHARE ANALYSIS
FIGURE 36 WEARABLE INJECTORS MARKET SHARE, BY KEY PLAYER, 2020
12.4 COMPETITIVE SCENARIO
12.4.1 PRODUCT LAUNCHES
TABLE 87 WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES (JANUARY 2018 TO JULY 2021)
12.4.2 DEALS
TABLE 88 WEARABLE INJECTORS MARKET: DEALS (JANUARY 2018 TO JULY 2021)
12.4.3 OTHER DEVELOPMENTS
TABLE 89 WEARABLE INJECTORS MARKET: OTHER DEVELOPMENTS (JANUARY 2018 TO JULY 2021)
12.5 COMPETITIVE BENCHMARKING
12.6 COMPANY EVALUATION MATRIX
12.6.1 STARS
12.6.2 EMERGING LEADERS
12.6.3 PERVASIVE PLAYERS
12.6.4 EMERGING COMPANIES
FIGURE 37 WEARABLE INJECTORS MARKET: GLOBAL COMPANY EVALUATION MATRIX
12.7 COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS)
12.7.1 PROGRESSIVE COMPANIES
12.7.2 STARTING BLOCKS
12.7.3 RESPONSIVE COMPANIES
12.7.4 DYNAMIC COMPANIES
FIGURE 38 WEARABLE INJECTORS MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS
13 COMPANY PROFILES (Page No. - 140)
13.1 KEY PLAYERS
(Business Overview, Products, Key Insights, Recent Developments, MnM View)*
13.1.1 AMGEN INC.
TABLE 90 AMGEN INC.: BUSINESS OVERVIEW
FIGURE 39 AMGEN INC.: COMPANY SNAPSHOT (2020)
13.1.2 MEDTRONIC PLC
TABLE 91 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 40 MEDTRONIC PLC: COMPANY SNAPSHOT (2020)
13.1.3 INSULET CORPORATION
TABLE 92 INSULET CORPORATION: BUSINESS OVERVIEW
FIGURE 41 INSULET CORPORATION: COMPANY SNAPSHOT (2020)
13.1.4 BECTON, DICKINSON AND COMPANY
TABLE 93 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
13.1.5 YPSOMED
TABLE 94 YPSOMED: BUSINESS OVERVIEW
FIGURE 43 YPSOMED: COMPANY SNAPSHOT (2020)
13.1.6 UNITED THERAPEUTICS CORPORATION
TABLE 95 UNITED THERAPEUTICS CORPORATION: BUSINESS OVERVIEW
FIGURE 44 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2020)
13.1.7 SUBCUJECT
TABLE 96 SUBCUJECT: BUSINESS OVERVIEW
13.1.8 ENABLE INJECTIONS
TABLE 97 ENABLE INJECTIONS: BUSINESS OVERVIEW
13.1.9 CEQUR SA
TABLE 98 CEQUR SA: BUSINESS OVERVIEW
13.1.10 SENSILE MEDICAL (A PART OF GERRESHEIMER)
TABLE 99 SENSILE MEDICAL: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 STEADYMED THERAPEUTICS
TABLE 100 STEADYMED THERAPEUTICS: BUSINESS OVERVIEW
13.2.2 ATS AUTOMATION
TABLE 101 ATS AUTOMATION: BUSINESS OVERVIEW
FIGURE 45 ATS AUTOMATION: COMPANY SNAPSHOT (2020)
13.2.3 WEST PHARMACEUTICAL SERVICES, INC.
TABLE 102 WEST PHARMACEUTICAL SERVICES, INC.: BUSINESS OVERVIEW
FIGURE 46 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2020)
13.2.4 UNILIFE CORPORATION
TABLE 103 UNILIFE CORPORATION: BUSINESS OVERVIEW
13.2.5 TANDEM DIABETES CARE
TABLE 104 TANDEM DIABETES CARE: BUSINESS OVERVIEW
FIGURE 47 TANDEM DIABETES CARE: COMPANY SNAPSHOT (2020)
13.2.6 VALERITAS, INC.
TABLE 105 VALERITAS, INC.: BUSINESS OVERVIEW
FIGURE 48 VALERITAS, INC.: COMPANY SNAPSHOT (2020)
13.2.7 BÜHLER MOTOR GMBH
TABLE 106 BÜHLER MOTOR GMBH: BUSINESS OVERVIEW
FIGURE 49 BÜHLER MOTOR GMBH: COMPANY SNAPSHOT (2020)
13.2.8 SONCEBOZ
TABLE 107 SONCEBOZ: BUSINESS OVERVIEW
13.2.9 NOBLE INTERNATIONAL LLC (AN APTAR PHARMA COMPANY)
TABLE 108 NOBLE INTERNATIONAL LLC: BUSINESS OVERVIEW
FIGURE 50 NOBLE INTERNATIONAL LLC: COMPANY SNAPSHOT (2020)
13.2.10 ELCAM DRUG DELIVERY DEVICES (E3D)
TABLE 109 ELCAM DRUG DELIVERY DEVICES: BUSINESS OVERVIEW
13.2.11 BESPAK EUROPE LTD.
TABLE 110 BESPAK EUROPE LTD.: BUSINESS OVERVIEW
FIGURE 51 BESPAK EUROPE LTD.: COMPANY SNAPSHOT (2020)
13.2.12 STEVANATO GROUP
TABLE 111 STEVANATO GROUP: BUSINESS OVERVIEW
13.2.13 SORREL MEDICAL
TABLE 112 SORREL MEDICAL: BUSINESS OVERVIEW
13.2.14 WEIBEL CDS
TABLE 113 WEIBEL CDS: BUSINESS OVERVIEW
13.2.15 NEUMA LLC
TABLE 114 NEUMA: BUSINESS OVERVIEW
*Details on Business Overview, Products, Key Insights, Recent Developments, MnM View might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 187)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
